The Enterprise Value as of December 2024 (TTM) for Pardes Biosciences, Inc. (PRDS) is 75.90M

According to Pardes Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 75.90M. This represents a change of -1647.66% compared to the average of -4904295.38 of the last 4 quarters.

Pardes Biosciences, Inc. (PRDS) Historical Enterprise Value (quarterly & annually)

How has PRDS Enterprise Value performed in the past?

The mean historical Enterprise Value of Pardes Biosciences, Inc. over the last ten years is -56974145.38. The current 75.90M Enterprise Value has changed -13422.13% with respect to the historical average. Over the past ten years (40 quarters), PRDS's Enterprise Value was at its highest in in the December 2021 quarter at 660.57M. The Enterprise Value was at its lowest in in the September 2022 quarter at -101048451.70.

Pardes Biosciences, Inc. (PRDS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Pardes Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Pardes Biosciences, Inc. (PRDS) Average Enterprise Value

How has PRDS Enterprise Value performed in the past?

The current Enterprise Value of Pardes Biosciences, Inc. (PRDS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Pardes Biosciences, Inc. (PRDS) Enterprise Value vs. Peers

How is PRDS’s Enterprise Value compared to its peers?

Pardes Biosciences, Inc.’s Enterprise Value is greater than Shattuck Labs, Inc. (12.78M), less than Eliem Therapeutics, Inc. (0), less than Champions Oncology, Inc. (115.62M), less than Century Therapeutics, Inc. (88.31M), greater than Neoleukin Therapeutics, Inc. (-6333315.00), less than Instil Bio, Inc. (217.29M), greater than Achilles Therapeutics plc (-35783455.00), greater than NextCure, Inc. (4.85M), greater than Assembly Biosciences, Inc. (68.46M), greater than CytomX Therapeutics, Inc. (54.93M), less than Nuvation Bio Inc. (894.94M), greater than Ovid Therapeutics Inc. (68.42M), greater than Connect Biopharma Holdings Limited (-53600395.00),

Build a custom stock screener for Pardes Biosciences, Inc. (PRDS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pardes Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Pardes Biosciences, Inc. (PRDS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Pardes Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.